Literature DB >> 34629715

Radioembolization for the Treatment of Hepatocellular Carcinoma: The Road to Personalized Dosimetry and Ablative Practice.

Cynthia De la Garza-Ramos1, Beau B Toskich1.   

Abstract

Radioembolization dosimetry for the treatment of hepatocellular carcinoma has evolved alongside our understanding of best practice for this therapy. At the core of advances in dosimetry are personalized and ablative applications of radioembolization, which have generated paradigm shifts in both safety and efficacy. This review provides a summary of fundamental radioembolization dosimetry concepts and narrates how our approach to treating patients has shifted from conventional to tailored and definitive therapy. Thieme. All rights reserved.

Entities:  

Keywords:  Y90; dosimetry; interventional radiology; liver cancer; radioembolization

Year:  2021        PMID： 34629715      PMCID： PMC8497084          DOI： 10.1055/s-0041-1735571

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN： 0739-9529            Impact factor:   1.780


  45 in total

1.  Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.

Authors:  Harun Ilhan; Anna Goritschan; Philipp Paprottka; Tobias F Jakobs; Wolfgang P Fendler; Andrei Todica; Peter Bartenstein; Marcus Hacker; Alexander R Haug
Journal:  J Nucl Med       Date:  2015-08-27       Impact factor: 10.057

2.  Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90Y in the SARAH Study.

Authors:  Anne-Laure Hermann; Arnaud Dieudonné; Maxime Ronot; Manuel Sanchez; Helena Pereira; Gilles Chatellier; Etienne Garin; Laurent Castera; Rachida Lebtahi; Valérie Vilgrain
Journal:  Radiology       Date:  2020-06-30       Impact factor: 11.105

3.  A Microdosimetric Analysis of Absorbed Dose to Tumor as a Function of Number of Microspheres per Unit Volume in 90Y Radioembolization.

Authors:  Alexander S Pasciak; Austin C Bourgeois; Yong C Bradley
Journal:  J Nucl Med       Date:  2016-02-18       Impact factor: 10.057

Review 4.  Y90 Radioembolization Dosimetry: Concepts for the Interventional Radiologist.

Authors:  Beau Bosko Toskich; David M Liu
Journal:  Tech Vasc Interv Radiol       Date:  2019-02-27

5.  Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.

Authors:  Etienne Garin; Lambros Tselikas; Boris Guiu; Julia Chalaye; Julien Edeline; Thierry de Baere; Eric Assenat; Vania Tacher; Corentin Robert; Marie Terroir-Cassou-Mounat; Denis Mariano-Goulart; Giuliana Amaddeo; Xavier Palard; Antoine Hollebecque; Marilyne Kafrouni; Hélène Regnault; Karim Boudjema; Serena Grimaldi; Marjolaine Fourcade; Hicham Kobeiter; Eric Vibert; Samuel Le Sourd; Lauranne Piron; Danièle Sommacale; Sophie Laffont; Boris Campillo-Gimenez; Yan Rolland
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-11-06

6.  A hepatic dose-toxicity model opening the way toward individualized radioembolization planning.

Authors:  Stephan Walrand; Michel Hesse; Francois Jamar; Renaud Lhommel
Journal:  J Nucl Med       Date:  2014-06-05       Impact factor: 10.057

7.  Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.

Authors:  Paul Haste; Mark Tann; Scott Persohn; Thomas LaRoche; Vasantha Aaron; Thibault Mauxion; Nikhil Chauhan; Matthew R Dreher; Matthew S Johnson
Journal:  J Vasc Interv Radiol       Date:  2017-02-24       Impact factor: 3.464

8.  Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up.

Authors:  J C Andrews; S C Walker; R J Ackermann; L A Cotton; W D Ensminger; B Shapiro
Journal:  J Nucl Med       Date:  1994-10       Impact factor: 10.057

9.  Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus.

Authors:  Leandro Cardarelli-Leite; John Chung; Darren Klass; Vladimir Marquez; Frank Chou; Stephen Ho; Henry Walton; Howard Lim; Peter Tae Wan Kim; Anastasia Hadjivassiliou; David M Liu
Journal:  Cardiovasc Intervent Radiol       Date:  2020-01-06       Impact factor: 2.740

Review 10.  The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres.

Authors:  Mark A Westcott; Douglas M Coldwell; David M Liu; Joseph F Zikria
Journal:  Adv Radiat Oncol       Date:  2016-08-18
View more
  2 in total

1.  TNF-α Indicates Radiation-induced Liver Injury After Interstitial High Dose-rate Brachytherapy.

Authors:  Robert Damm; Maciej Pech; Florian Haag; Paola Cavalli; Severin Gylstorff; Jazan Omari; Ricarda Seidensticker; Jens Ricke; Max Seidensticker; Borna Relja
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

2.  Correlation of chemokines and growth factors with radiation-induced liver injury after interstitial high dose rate (HDR) brachytherapy of liver metastases.

Authors:  Robert Damm; Maciej Pech; Paola Cavalli; Florian Haag; Severin Gylstorff; Jazan Omari; Maximilian Thormann; Ricarda Seidensticker; Jens Ricke; Max Seidensticker; Borna Relja
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-21       Impact factor: 4.322
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.